Allay Therapeutics is pioneering products to help patients recover from post-surgical pain management. Current pain management products provide several days of pain relief, much shorter than the weeks or months of post-surgical recuperation that millions of patients cope with. To resolve this, Allay has developed the first technology designed to deliver weeks of localized pain management. Allay’s proprietary technology combines validated non-opioid analgesics and biopolymers to create candidates that deliver targeted pain relief. By tuning the drug-biopolymer architecture that alters the analgesic release profile, Allay can design their technology for a variety of potential applications. Allay’s lead candidate, ATX-101, is designed to support recuperation from total knee-replacement surgery.

<p>Allay Therapeutics is pioneering products to help patients recover from post-surgical pain management. Current pain management products provide several days of pain relief, much shorter than the weeks or months of post-surgical recuperation that millions of patients cope with. To resolve this, Allay has developed the first technology designed to deliver weeks of localized pain management. Allay’s proprietary technology combines validated non-opioid analgesics and biopolymers to create candidates that deliver targeted pain relief. By tuning the drug-biopolymer architecture that alters the analgesic release profile, Allay can design their technology for a variety of potential applications. Allay’s lead candidate, ATX-101, is designed to support recuperation from total knee-replacement surgery.</p>


Allay Therapeutics

SINGAPORE’S NEXT CHALLENGE: TURNING MOMENTUM INTO SUSTAINABLE GROWTH

As Chief Medical Officer of Allay Therapeutics, David Hewitt, has been a visionary force in advancing clinical development in the pain management field.  

With over two decades of experience, David brings a unique background that combines neurology expertise and an impressive track record in pharmaceutical clinical development. His work spans roles from Senior VP at Nura Bio to pivotal leadership in neuroscience and pain management at Syneos Health, Karuna Therapeutics, and Merck. Among his notable accomplishments, David led the pediatric migraine program that achieved FDA approval for Maxalt and contributed to the innovative drug-device system, Ionsys, for postoperative pain. His dedication to pioneering therapies that meaningfully impact patients’ lives is central to Allay’s mission to transform pain care. 

Learn more about our team here: https://lnkd.in/eF4k62RZ

Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform

Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan

Allay Therapeutics Receives FDA Breakthrough Therapy Designation (BTD) for ATX101 for the Treatment of Post-surgical Pain Following Total Knee Replacement Surgery - Business Wire

The Allay Therapeutics team, thanks to our partnership with Life Science Cares Bay Area, had the privilege of volunteering at Second Harvest of Silicon Valley to help provide meals for those in need. Second Harvest now serves over 450,000 Santa Clara County and San Mateo County residents each month, an 80% increase over pre-pandemic numbers. 

As we approach Thanksgiving and the holiday season, it’s a poignant reminder of how important it is to give back to our community. Helping others is at the heart of our values, and we’re incredibly proud to support an organization that works tirelessly to combat food insecurity in our community. 

A heartfelt thank you to Second Harvest for all that you do and for allowing us to be part of this important mission. Together, we can make a difference in the lives of those around us. 

#AllayTherapeutics #TeamAllay #Biotech #CommunityImpact 

No opioids after surgery: Evonik invests in Allay Therapeutics and supplies key technology for pain therapy implants

 Allay Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application to Initiate Pivotal Phase ... 

https://venturing.evonik.com

Phase 2B Study Data for 4-Week TKA Analgesic - https://ryortho.com/

Allay Therapeutics’ Phase 2B Clinical Study Supports Ability of ATX101 To Deliver Four Weeks of Sustained Post-surgical Pain Relief - Business Wire

Our CEO, Adam Gridley, joined our partner Maruishi Pharmaceutical Co.,Ltd. and their investigators in Osaka for a meeting focused on advancing Allay’s groundbreaking work in post-surgical pain management into clinical trials in Japan.   
 
It was a valuable opportunity to share insights, discuss study outcomes, and collaborate with top minds in orthopedic surgery and pain management. This gathering marked another step forward for the ATX101 global clinical development program and our goal to provide sustained non-opioid pain relief.  
  
A heartfelt thank you to our partner and their investigators for their continued support and expertise as we drive Allay’s mission of transforming patient recovery. Learn more about our ATX101 program here: https://lnkd.in/gm2wvi7n   
 
#AllayTherapeutics #PainManagement #Orthopedics

Clinical report: Proof of concept for Allay’s implantable analgesic, with Singapore tech - BioCentury

We were pleased to bring our newly expanded Scientific Advisory Board (SAB) together for our annual in-person meeting in Dallas, TX.  Our advisors, R&D, Regulatory and Manufacturing teams shared our progress on ATX101, our scaling plans for our upcoming Phase 3 studies in the US and Japan, as well as updates on our pipeline of ultra-sustained products to treat post-surgical pain.  
 
SAB members include Art Tipton, Dr. Christine Allen, Ronald M. Burch, MD, PhD, Joachim Kohn and Louis Lazo Radulovic.  

Allay Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application to Initiate Pivotal Phase 2B Trial of ATX101 for the Treatment of Post-surgical Pain Following Total Knee Replacement Surgery

Allay Therapeutics Announces Expansion of Clinical and Scientific Advisory Boards to Support the Company’s Mission to Transform Post-Surgical Pain Management

Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan - Business Wire

 Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan 

 Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform 

 Allay Therapeutics Appoints David Hewitt, M.D. as Chief Medical Officer 

Heron Therapeutics’ combo drug for post-surgical pain wins FDA nod on third try - MedCity News

 In 2019 completed a $25 million Series B financing led by NEA, with additional participation by Lightstone Ventures and Brandon Capital Partners 

Allay Therapeutics Establishes Corporate Headquarters in the Bay Area and Expands Base of Operations in Singapore

Allay Therapeutics Appoints Ron Burch, M.D., Ph.D. to Scientific Advisory Board

Allay Therapeutics Announces Expansion of Clinical and Scientific Advisory Boards to Support the Company’s Mission to Transform Post-Surgical Pain Management - Business Wire

 Allay Therapeutics Appoints Nicole Vitullo to Board of Directors 

Allay Therapeutics Appoints David Hewitt, M.D. as Chief Medical Officer

Allay Therapeutics Receives FDA Breakthrough Therapy Designation (BTD) for ATX101 for the Treatment of Post-surgical Pain Following Total Knee Replacement Surgery

Allay Therapeutics Launches with First Clinical Data to Demonstrate Weeks of Pain Relief with Ultra-Sustained Non-Opioid Platform

Another great visit to Singapore to visit our local Allay Therapeutics team, our investors, and to attend an excellent ClavystBio event. We enjoyed collaborating with the team on planning and project development – and couldn’t miss celebrating several birthdays! We also were thrilled to meet with our supportive investors at Vertex Growth, ClavystBio, and Pavilion Capital to share our latest progress with our lead candidate ATX101. 
 
One of the highlights of the week was the #clavystbioconnects ClavystBio Portfolio Day and networking event. Yingmin Wang hosted an insightful panel with Adam Gridley, Theresa Heah and Piers Ingram where we discussed the learnings and challenges of scaling early-stage companies globally. A big thanks to Khoo Shih, Yingmin and the entire ClavystBio team for the compelling discussions with leading investors, partners and portfolio companies on the opportunities within the Singapore life sciences ecosystem.

#PainManagement #Biotech #AllayTherapeutics

As Allay’s clinical program advances, we recently hosted an Investigator Meeting for our upcoming Phase 2B study on ATX 101, our lead candidate in post-surgical pain relief. Designed to address the challenges of sustained, non-opioid analgesia, ATX 101 supports faster recovery times and less dependence on traditional pain management methods. 

This meeting wouldn’t have been possible without our incredible clinical team, whose expertise and commitment continue to drive Allay’s progress. We appreciate your dedication to improving patient outcomes and advancing innovative solutions in pain care. 

Learn more about our pipeline here: www.allaytx.com/pipeline 

#AllayTherapeutics #PainManagement #Orthopedics

Allay Therapeutics rakes in $60M for 'tunable' non-opioid ...

Brandon Capital raises $180M fund to support Australia, New Zealand biotechs - Fierce Biotech

 Allay Therapeutics' Phase 2B Clinical Study Supports Ability of ATX101 To Deliver Four Weeks of Sustained Post ... 

Evonik invests in pain relief implant developer Allay - Chemical & Engineering News

Evonik backs Allay's development of postsurgery pain therapy implants - FiercePharma

Allay Therapeutics Establishes Corporate Headquarters in the Bay Area and Expands Base of Operations in Singapore - Business Wire

Allay Therapeutics rakes in $60M for 'tunable' non-opioid treatment for joint replacement pain - Fierce Biotech

Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform - Business Wire

We’re proud to announce that the U.S. FDA has granted Breakthrough Therapy designation (BTD) for ATX101, our investigational treatment for post-surgical pain following total knee replacement (TKA) surgeries. This news highlights the urgent need for non-opioid alternatives in managing post-surgical pain and the potential of ATX101 to provide extended pain relief, limiting opioid use and associated side effects. 
 
This designation is supported by promising results from a Phase 2 dose-ranging trial, which demonstrated that ATX101 delivers up to 4 weeks of sustained pain relief, as well as clinically meaningful improvements in functional activity and patient satisfaction.
 
We’re looking forward to progressing to the registrational Phase 2B trial and working closely with the FDA to advance the development of ATX101 to patients in need.
 
Read more in today’s release: https://lnkd.in/eYQ_S3az 

NEA-backed Allay exits stealth with clinical pain data ...

 Allay Therapeutics Receives FDA Breakthrough Therapy Designation (BTD) for ATX101 for the Treatment of Post-surgical Pain Following Total Knee Replacement Surgery 

Temasek invests in US biotech firm Allay Therapeutics - The Straits Times

Allay Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application to Initiate Pivotal Phase 2B Trial of ATX101 for the Treatment of Post-Surgical Pain Following Total Knee Replacement Surgery - Business Wire

As we reflect on 2024, we are incredibly grateful for the dedication of our team, the trust of our partners, and the support of our community. Together, we’ve reached new milestones in pain management, deepened our impact in post-surgical care, and moved closer to transforming recovery for patients. 

This holiday season, we want to thank everyone who has been part of our journey—our team, partners, and community. Here’s to a bright new year filled with health, innovation, and continued progress toward our mission. 

Happy holidays from Allay Therapeutics! 

#AllayTherapeutics #TeamAllay #Biotech

Allay Therapeutics Appoints Nicole Vitullo to Board of Directors

Allay Therapeutics was pleased to join this year’s American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting in Dallas, TX!  

Allay’s CMO David Hewitt and Investigators attended AAHKS to share a poster presentation from our recently completed Phase 2B Part A study entitled “ATX101 provides sustained pain relief in TKA patients: results of a multicenter double-blind RCT." This study demonstrated compelling results on patient’s pain, opioid usage and function after TKA surgeries. These data supported the opening of our IND in the US and our dose selection for our upcoming Phase 2B Part B study.    

Our team enjoyed connecting with leading experts in hip and knee surgery as we continue to transform post-surgical pain management and recuperation. Thank you to AAHKS for hosting this important event. 

#AAHKS #AAHKS24 #Biotech #Orthopedics

ALLAY THERAPEUTICS: A SITE-SPECIFIC DRUG IMPLANT TREATS POSTSURGICAL PAIN

Our inaugural Portfolio Day brought together our Board, portfolio companies, and partners for an inspiring day of networking, insightful discussions, and shared learnings on building global life science companies.

This milestone event capped off a year of forging new connections, deepening partnerships, and driving our mission to advance health impact.

We’re excited to continue building momentum with our incredible community!

#ClavystBioConnects #Innovation #HealthImpact
Accelerator Life Science Partners Allay Therapeutics Automera Droia Ventures Engine Biosciences Hummingbird Bioscience Leyden Labs Lightstone Ventures MediSix Therapeutics NSG BioLabs Nuevocor Paratus Sciences Polaris Partners Quilt Sunbird Bio Evotec BRIDGEs #65LAB

Allay’s ATX101 offers post-surgical pain relief in Phase IIB trial - Clinical Trials Arena

Allay Therapeutics

Business:

Drug notes:

About: